QuidelOrtho Corporation which can be found using ticker (QDEL) now have 7 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between 168 and 81 and has a mean target at $118.14. Now with the previous closing price of $69.21 and the analysts are correct then there would likely be a percentage uptick in value of 70.7%. Also worth taking note is the 50 day moving average now sits at $75.81 and the 200 day MA is $84.16. The market capitalization for the company is 4.62B. The stock price for the company is currently 64.94 USD
The potential market cap would be $7,890,644,512 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of 47.43 and a 2.41% return on assets.
QuidelOrtho Corporation is a vitro diagnostics company. The Company is engaged in the development and manufacturing of advanced technologies in diagnostic testing. Its capabilities include immunoassay and molecular testing, clinical chemistry and transfusion medicine. The Company’s business units include Labs, Molecular Diagnostics, Point of Care, and Transfusion Medicine. Its Labs business unit includes Virology, Specialty Products, Specialty Products, Immunodiagnostics, VITROS Platform, XT Platform, VITROS XT Platform, and VITROS Automation Solutions. Its Molecular Diagnostics business includes Lyra, Solana, and Savanna. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, D, ELVIRA, ELVIS, FastPoint, FreshCells, InflammaDry, Lyra, MicroVue, Ortho, Ortho Clinical Diagnostics, Ortho Vision, Quidel, QuickVue, QuickVue+, QVue, ReadyCells, Savanna, Sofia, Solana, Thyretain, Triage, Virena, and Vitros.
